Search Within

Connie Wing-Ching Lee Batlevi

Formats
  1. Meeting Abstract (109)
  2. Journal Article (52)
  3. Research Letter (5)
  4. Book Section (4)
  5. Miscellaneous (2)
  6. Review (2)
  7. Correspondence (1)
  8. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (176)
  2. Department of Medicine (176)
  3. Hematologic Malignancies, Division of (176)
  4. Lymphoma (176)
  5. Survivorship Research (117)
  6. Epidemiology and Biostatistics (89)

More Groups

People
  1. Maria Palomba (98)
  2. Anas Younes (81)
  3. Andrew Zelenetz (76)
  4. Matthew Matasar (70)
  5. David Straus (61)
  6. Ariela Noy (60)

More People

Years
  1. 2024 (2)
  2. 2023 (11)
  3. 2022 (30)
  4. 2021 (27)
  5. 2020 (27)
  6. 2019 (34)

More Years

Publications
  1. Blood (69)
  2. Hematological Oncology (16)
  3. Blood Advances (12)
  4. Journal of Clinical Oncology (10)
  5. Blood Cancer Journal (6)
  6. Biology of Blood and Marrow Transplantation (5)

More Publications

Publishers
  1. American Society of Hematology (82)
  2. Wiley Blackwell (16)
  3. Elsevier Inc. (15)
  4. Nature Publishing Group (15)
  5. American Society of Clinical Oncology (10)
  6. John Wiley & Sons (4)

More Publishers

Results (176)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy
    Journal Article

    Shouval, R.; Alarcon Tomas, A.; Fein, J. A.; Flynn, J. R.; Markovits, E.; Mayer, S.; Afuye, A. O.; Alperovich, A.; Anagnostou, T.; Besser, M. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schòˆder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: A multicenter observational study
    Meeting Abstract

    Tomas, A. A.; Fein, J. A.; Fried, S.; Fingrut, W.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; Lin, R. J.; Scordo, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save